Rigel Pharma (RIGL) Shares Tick Lower Early Following Strong Tostamatinib Data-Related Trading

August 31, 2016 8:45 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Rigel Pharma (NASDAQ: RIGL) shares are pulling back following a 49 percent gain on Tuesday. The stock is down around 4 percent.

Yesterday, Rigel announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Add Your Comment